Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Eritoran> ?p ?o. }
Showing items 1 to 56 of
56
with 100 items per page.
- Eritoran abstract "Eritoran is an investigational drug for the treatment of severe sepsis, an excessive inflammatory response to an infection. It is being developed by the Japanese pharmaceutical company Eisai Co. and administered intravenously as the sodium salt eritoran tetrasodium.In a phase III clinical trial, eritoran did not perform better than existing treatments for the treatment of sepsis.".
- Eritoran atcPrefix "none".
- Eritoran casNumber "185955-34-4".
- Eritoran casSupplemental "(tetrasodium salt)".
- Eritoran fdaUniiCode "551541VI0Y".
- Eritoran iupacName "[(2R,3R,4R,5S,6R)-4-Decoxy-5-hydroxy-6-[[(2R,3R,4R,5S,6R)-4-[(3R)-3-methoxydecoxy]-6-(methoxymethyl)-3-(Z)-octadec-11-enoyl]amino]-5-phosphonatooxyoxan-2-yl]oxymethyl]-3-(3-oxotetradecanoylamino)oxan-2-yl] phosphoric acid".
- Eritoran pubchem "6912404".
- Eritoran thumbnail Eritoran_free_acid_skeletal.svg?width=300.
- Eritoran wikiPageID "25562993".
- Eritoran wikiPageRevisionID "600903177".
- Eritoran atcPrefix "none".
- Eritoran c "66".
- Eritoran casNumber "185955".
- Eritoran chembl "501259".
- Eritoran h "126".
- Eritoran hasPhotoCollection Eritoran.
- Eritoran iupacName "[-4-Decoxy-5-hydroxy-6-[[-4-[-3-methoxydecoxy]-6--3-(Z)-octadec-11-enoyl]amino]-5-phosphonatooxyoxan-2-yl]oxymethyl]-3-(3-oxotetradecanoylamino)oxan-2-yl] phosphoric acid".
- Eritoran legalStatus "Investigational".
- Eritoran molecularWeight "1313.656".
- Eritoran n "2".
- Eritoran o "19".
- Eritoran p "2".
- Eritoran pubchem "6912404".
- Eritoran routesOfAdministration Intravenous_therapy.
- Eritoran smiles "CCCCCCCCCCCCCCNC1COCCCCCCCCCC".
- Eritoran stdinchi "1".
- Eritoran stdinchikey "BPSMYQFMCXXNPC-MFCPCZTFSA-N".
- Eritoran synonyms "E 5564".
- Eritoran unii "551541".
- Eritoran verifiedfields "changed".
- Eritoran verifiedrevid "394816802".
- Eritoran watchedfields "changed".
- Eritoran subject Category:Immunosuppressants.
- Eritoran type Agent114778436.
- Eritoran type CausalAgent100007347.
- Eritoran type Drug103247620.
- Eritoran type Immunosuppressant103562958.
- Eritoran type Immunosuppressants.
- Eritoran type Matter100020827.
- Eritoran type Medicine103740161.
- Eritoran type PhysicalEntity100001930.
- Eritoran type Substance100020090.
- Eritoran type Drug.
- Eritoran type DrugProduct.
- Eritoran type FunctionalSubstance.
- Eritoran comment "Eritoran is an investigational drug for the treatment of severe sepsis, an excessive inflammatory response to an infection. It is being developed by the Japanese pharmaceutical company Eisai Co. and administered intravenously as the sodium salt eritoran tetrasodium.In a phase III clinical trial, eritoran did not perform better than existing treatments for the treatment of sepsis.".
- Eritoran label "Eritoran".
- Eritoran label "エリトラン".
- Eritoran sameAs エリトラン.
- Eritoran sameAs m.09rsw42.
- Eritoran sameAs Q5389586.
- Eritoran sameAs Q5389586.
- Eritoran sameAs Eritoran.
- Eritoran wasDerivedFrom Eritoran?oldid=600903177.
- Eritoran depiction Eritoran_free_acid_skeletal.svg.
- Eritoran isPrimaryTopicOf Eritoran.